By Turna Ray

Myriad Genetics' recent investments to bolster the visibility of its molecular diagnostics products beyond its flagship BRACAnalysis test appear to be paying off.

For the three months ended Sept. 30, the first quarter of the company's 2012 fiscal year, revenues for Myriad's Colaris and Colaris AP tests for gauging the risk of hereditary colorectal cancer increased 35 percent to $9.6 million, outpacing the company's overall revenue growth of 20 percent to $111 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.